We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
(+18%)
Cap. Flow
+$342M
Cap. Flow
% of AUM
9.57%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Avg Time Held Equity + Options
4.4
quarters
Top 10 Avg Time Held Equity + Options
5.6
quarters
Top 20 Avg Time Held Equity + Options
4.8
quarters
Avg Time Held Equity only
4.7
quarters
Top 10 Avg Time Held Equity only
5.6
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$104M |
| 2 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$79.7M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$55.2M |
| 4 |
YARW
Yarrow Bioscience
YARW
|
+$54M |
| 5 |
Amicus Therapeutics
FOLD
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$58.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$25.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$24.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$24.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.46% |
| 2 | Miscellaneous | 1.79% |
| 3 | Consumer Staples | 0.67% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
HUTCHMED
HCM
$2.36B
| $296K | 0.01% |
10,000
| – | – |
2017 Q3
2 quarters
|
|
127
Vericel Corp
VCEL
$2.05B
| $271K | 0.01% |
+27,211
| New | +$225K |
2018 Q1
0 quarters
|
|
128
Grace Therapeutics
GRCE
$41.4M
| $190K | 0.01% |
3,887
| – | – |
2013 Q3
18 quarters
|
|
|
SGYP
129
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $183K | 0.01% |
+100,000
| New | +$211K |
2018 Q1
0 quarters
|
|
130
DELISTED
CASI Pharmaceuticals
CASI
| $182K | 0.01% |
4,368
-4,000
| -48% | -$149K |
2017 Q4
1 quarter
|
|
|
PTLA
131
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $158K | ﹤0.01% |
+100,000
| New | +$4.39M |
2018 Q1
0 quarters
|
|
|
ONCS
132
DELISTED
OncoSec Medical Incorporated
ONCS
| $94K | ﹤0.01% |
+227
| New | +$93.1K |
2018 Q1
0 quarters
|
|
133
CALL
Biogen
BIIB
$34.1B
| $11K | ﹤0.01% |
+50,000
| New | +$15.5M |
2018 Q1
0 quarters
|
|
134
Capricor Therapeutics
CAPR
$385M
| $5K | ﹤0.01% |
400
| – | – |
2017 Q4
1 quarter
|
|
135
DELISTED
Affimed
AFMD
| – | – |
-66,821
| Closed | -$869K | – |
|
136
Align Technology
ALGN
$10.1B
| – | – |
-3,448
| Closed | -$766K | – |
|
137
Amgen
AMGN
$231B
| – | – |
-50,000
| Closed | -$8.7M | – |
|
138
Bausch Health
BHC
$2.23B
| – | – |
-30,092
| Closed | -$625K | – |
|
139
DELISTED
bluebird bio
BLUE
| – | – |
-1,112
| Closed | -$2.56M | – |
|
140
Centene
CNC
$34B
| – | – |
-13,398
| Closed | -$676K | – |
|
141
Corbus Pharmaceuticals
CRBP
$89.9M
| – | – |
-6,667
| Closed | -$1.42M | – |
|
142
Curis
CRIS
$1.47M
| – | – |
-476
| Closed | -$666K | – |
|
143
Evolent Health
EVH
$523M
| – | – |
-50,000
| Closed | -$615K | – |
|
144
Exelixis
EXEL
$15.1B
| – | – |
-46,361
| Closed | -$1.41M | – |
|
145
Globus Medical
GMED
$10.1B
| – | – |
-113,100
| Closed | -$4.65M | – |
|
146
Lantheus
LNTH
$6.53B
| – | – |
-53,763
| Closed | -$1.1M | – |
|
147
Quanterix
QTRX
$150M
| – | – |
-169,400
| Closed | -$3.64M | – |
|
148
Regeneron Pharmaceuticals
REGN
$78.8B
| – | – |
-20,000
| Closed | -$6.96M | – |
|
149
UroGen Pharma
URGN
$1.9B
| – | – |
-199,014
| Closed | -$7.41M | – |
|
|
150
Zimmer Biomet
ZBH
$17.4B
| – | – |
-206,000
| Closed | -$24.1M | – |
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $342M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.
- Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
- Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
- Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
- Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
- Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
- Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.
Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.